Access to Hospital Pharmaceutical Markets in the United Kingdom – Aarkstore Enterprise

Public hospitals represent a very important market segment for most biopharmaceutical companies in Europe. They are the often the only market for the increasing numbers of speciality drugs emerging from R&D, with many primary care products also unable to get established for maintenance therapy in the community without hospital recommendation first. Though the processes for achieving hospital usage are very different to the reimbursed GP/community pharmacy sector, they have been poorly documented and often little understood. This justpharmareports’ publication aims to clarify the situation for the UK, a particularly challenging country with four different public healthcare systems, numerous stakeholders, regular reforms, and rigorous health technology assessment.

Medicines prescribed in English hospitals in 2006 were valued at £2.7 billion. This represented 24% of the English NHS drugs bill (hospital prescribing in London alone accounted for 40% of all prescribing costs in the capital). Even more significantly, the hospital drug bill has been rising at more than twice the rate of GP prescribing costs.

‘Access to Hospital Pharmaceutical Markets in the UK’ provides:

• Comprehensive and clear information on how medicines for hospital use get selected, purchased, distributed, prescribed, dispensed and paid for.
• Separate sections on England, Scotland, Wales and Northern Ireland.
• Full coverage of the NHS plus two of the largest private providers.
• Explanation of tendering, contracting, contract adjudication and other aspects of procurement for both brands and generics.
• Clarification of the complex English funding system, Payment by Results.
• Special focus on oncology.

• What discounts hospitals expect and why value-added tax is a concern.
• Features on risk-sharing schemes and on the boom in homecare services.
• NICE, SMC, AWMSG, the PPRS and much, much more

http://www.aarkstore.com/reports/Access-to-Hospital-Pharmaceutical-Markets-in-the-United-Kingdom-1052.html

Wound Care Markets, 4th. Edition, Vol. I: Skin Ulcers – Aarkstore Enterprise

Wound care is a constantly changing market. The trend toward cost-effective skin ulcer treatment remains embedded in management programs that emphasize prevention and early intervention. New wound care products and devices are entering the market with lightening speed, all striving for the best clinical outcomes. Kalorama’s Wound Care Markets, 4th Edition, Vol. I: Skin Ulcers. represents the fourth time that Kalorama has rexamined this aspect of the wound care market, and the study analyzes the market using the following product segments and subsegments:

• Anti-Infectives
  • Systemic
  • Topical
• Skin Ulcer Management
  • Compression Dressings and Bandages
  • Wound Cleaners
  • Debridement
• Moist Dressings
  • Alginates
  • Films
  • Foams
  • Hydrocolloids
  • Hydrogels
• Negative Pressure Wound Therapy
• Biological Dressings
  • Artificial Skin
  • Collagen
  • Growth Factors
  • Others
• Pressure Relief
• Miscellaneous Treatments

For each segment and subsegment, the report gives current market size and forecasted revenues years 2009 through 2013. Competitive market share information is provided by leading manufacturer for each major segment in the year 2006. Historical data are provided for each of the years 2003 through 2008. The study also details research developments, industry trends, and relevant epidemiologic and demographic data.

Since the last edition of Kalorama Information’s Wound Care Markets Series, there have been shifts in the market for treatment of skin ulcers. Up-to-date information was obtained from coverage of the world-renown Symposium on Advanced Wound Care and the Wound Healing Society convention. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals and company reports and releases. Key information from published literature was used to conduct interviews with over 62 industry executives and product managers to validate and obtain expert opinion on current and future trends in the wound care industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.

All market data pertain to the market at the manufacturers’ level. Data are expressed in current U.S. dollars.

Marketing directors, product managers, business development executives in the wound care industry, investment specialists considering investments in this area and consultants and advertising agencies who service wound care clients are among those who will find this study a useful resource.

License Note: Kalorama Information’s listed default price on its information products reflects a single user license only. Purchasing a departmental or global site license (for entire company) permits multiple individuals in the company to benefit from this resource.

http://www.aarkstore.com/reports/Wound-Care-Markets-4th-Edition-Vol-I-Skin-Ulcers-13480.html

Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the United Kingdom

In an otherwise volatile pharmaceutical world, 2009 has seen two notable and durable anniversaries, the implementation of the tenth re-negotiated Pharmaceutical Price Regulation Scheme in January and the tenth birthday of the National Institute for Health and Clinical Excellence in April. PPRS and NICE, are among abbreviations most widely recognised, but their structures, functions and ways of working are often less than fully understood.

‘Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the UK’ delivers what it says in the title. It provides in one place fully-researched, up-to-date information and interpretation on all the market access barriers facing pharmaceutical companies in the four countries that make up the United Kingdom.

The UK has a much bigger global impact in pricing and health technology assessment terms than its market size would suggest. It is a key lead-off one for launches. While accounting for less than 4% of world demand for prescription medicines, other countries that set prices with reference to those in the UK together account for 25% of that demand. Like them or hate them, the PPRS and NICE are original, well-established and influential models that governments and industry bodies elsewhere look to.

The report addresses:

• The UK’s complex decision-making processes for funding of medicines.

• The procedures and outcomes of the three HTA bodies, NICE, SMC and AWMSG.

• How and why the 2009 PPRS evolved in the way it did, and what this means for companies selling medicines to the NHS.

• The pros and cons of joining the voluntary or alternative statutory scheme.

• All the changes in the new PPRS and the prospects for the more novel but contentious parts, including flexible pricing, patient access schemes and generic substitution.

• What jargon including ‘end-of-life treatment’, ‘horizon scanning’, ‘NICE blight’,‘OFT wedge’ ‘outturn’, ‘QALY’, ‘safety value’ and ‘top-up’ actually mean.

• Other cost containment measures impacting on prescribers, patients and the distribution chain.

http://www.aarkstore.com/reports/Complete-Guide-to-the-2009-PPRS-NICE-other-Pharmaceutical-Cost-Containment-Measures-in-the-United-Kingdom-13490.html

Global Drug Infusion Pumps Market 2008-2012

Drug infusion pumps have a varied application in different environment and therapies. Due to this, a wide array of pumps are being manufactured and made available in the market. Thus, drug infusion pump manufacturers are realigning their marketing strategies and product delivery mechanism to appeal to the patients as well. With the abundant information available, patients have become more aware about healthcare issues, and can play an active role in the decision making process with their healthcare providers.

Developing countries hold potential growth prospects for drug infusion pumps market. The availability of cost effective and quality healthcare is driving the growth of medical tourism. Drug infusion pump manufacturers are focusing their strategies towards these emerging markets.
The report by TechNavio Insights forecasts the size of the Global Drug Infusion Pumps Market over the period 2008-2012. It segments the market into various geographic regions (representing the market size of each region). Further, it discusses the key market trends, driver and challenges of the Global Drug Infusion Pumps Market and profiles some of the key vendors of this market.

TechNavio Insights is a set of reports based on TechNavio – a market intelligence platform for the IT industry. It builds on the intelligence available within TechNavio, and leverages on the custom research experience of the ‘Technology Navigators’. TechNavio is built on years of experience of Infiniti Research in deep dive custom research and consulting for over 30 Fortune 500 companies and numerous large and mid-sized companies.

http://www.aarkstore.com/reports/Global-Drug-Infusion-Pumps-Market-2008-2012-19500.html

Pharmacogenomics for Clinical Use and in Drug Development – Aarkstore Enterprise

Pharmacogenomics, the science of individualizing drug therapy based on the genetic makeup of individual patients, offers an unusual opportunity for future market growth. Applying pharmacogenomics would allow doctors to treat specific segments of the population based on their particular responses to a drug. The knowledge of the likely effectiveness of a drug in a patient makes the drug more reliable, and fewer drugs would have to be taken off the market due to adverse reactions in some, but not all, of the patients to whom they were administered. Additionally, reducing the occurrence of adverse effects to a drug effectually reduces the cost of patient care overall. This Publications study examines the market for diagnostic tests based on this science and the clinical measurement methods, the reagents and supplies being utilized in clinical medicine and the pharmaceutical industry. This report presents an overview of the latest information regarding emerging new products and industry trends and will not only quantify, but also, qualify the pharmacogenomic market segments as an area of research, product development and investment opportunity. Forecasts of the pharmacogenomic market and an analysis of products in the worldwide diagnostics market will provide a basis for understanding the significance of past developments and the immense possibilities of the future.

For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Pharmacogenomics-for-Clinical-Use-and-in-Drug-Development-13789.html

Cell-Based Assays for Drug Discovery – Aarkstore Enterprise

The area of drug discovery tools is one of the newest and most important sectors of pharmaceutical research and development. The term drug discovery tools usually refers to high-content screening (HCS) and analysis and is composed of those applications that require sufficient levels of sample throughput, whereby complex cellular events and phenotypes can be studied. Elements of drug performance like toxicity and specificity can be established simultaneously using mixed cell types-primary cells, cell lines, cell subpopulations. HCS seeks to assess the impact of phenotypic and cellular changes that are brought about by gene modification (such as with RNA interference (RNAi) approaches) and/or drug (or compound) treatment. The purpose of this examination by TriMark Publications is to describe the specific segments of the global drug discovery tools market. Within this area, the report covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small lab equipment all the way up to highly automated, large automated platforms, as well as accessory equipment such as reagents, supplies and manufacturers’ original equipment manufacturer (OEM) additional equipment.
 
 
Table of Contents : 
 1. Overview 4
 1.1 Objectives of the Report 4
 1.2 Methodology 5
 1.3 Scope of the Report 6
 1.4 Executive Summary 7

 2. Technologies and Product Offering for High-Content Analysis 10
 2.1 Definition of High-Content Analysis and Why it is so Attractive a Discipline 11
 2.2 Classes of Measurements Possible with High-Content Analysis Approaches and Biologies Interrogated 14
 2.3 Instrumentation Platforms for High-Content Analysis 17
 2.3.1 High-Content Screening Technology 17
 2.4 Reagent and Assay Platforms for High-Content Analysis 24
 2.5 Cell-based Screening Technologies in Drug Development 28
 2.5.1 Applications of Cell-based Assays 28
 2.5.2 Pharma Drug Discovery Paradigm and Compound Screening 28
 2.5.3 High-Content Analysis in the Biopharmaceutical Industry 29

 3. Market Analysis of the High-Content Tools Space 31
 3.1 High-Content Analysis Market Size and Growth 31
 3.2 Market Survey to Assess Qualitative and Quantitative Parameters of the High-Content Analysis Space 31
 3.3 Experimental and Research Trends in High-Content Analysis 33
 3.4 Challenges and Market Drivers in High-Content Analysis 38
 3.4.1 Barriers to High-Content Analysis 40
 3.4.2 Drivers of High-Content Analysis 41
 3.5 High-Content Analysis in Combination with RNAi 41
 3.6 Market Landscape of Instrumentation for High-Content Analysis 43
 3.7 Reagents and Assays Usage in High-Content Analysis 47
 3.8 Trends in High-Content Analysis Assays/Reagents Space-Major Product Vendors 50
 3.9 Emerging Market Trends in High-Content Analysis 52
 3.10 Market Forecasts for the High-Content Analysis Space 54
 3.11 Use of HCS in Pharmaceutical Companies 56
 3.12 Qualitative Opportunities and Challenges for Market Adoption 57

 For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Cell-Based-Assays-for-Drug-Discovery-6634.html

Dental Equipment Market – Aarkstore Enterprise

The dental devices report forecasts the size of global dental equipment and consumables market over the period 2009 – 2014. The report analyses the key trends of the market, and segments the global dental equipment and consumables market by components and into various geographic regions (with the market size for each of these regions). Further, it discusses the key market drivers, restraints and opportunities of the global dental equipment and consumables market.

The global dental equipment and consumables market is estimated to be $26 billion by 2014, growing at a CAGR of 6.8%. The market is expected to grow because of the tremendous demand for dental biomaterial and dental implants. It is expected that the market for dental implants and dental biomaterials will grow at an overall CAGR of 12.2% and 10.5% respectively from 2009 – 2014. The main driving element for global dental equipment market is the advancement in technologies that are available to dentists’ for treating their patients.

The growth of this market is expected to be highest in the U.S. and EU where the generation of aging baby boomers can afford the quality but expensive dental procedures. This is also expected to be a catalyst for the growth and popularity of cosmetic treatments and implants along with the increasing demand for better orthodontic products by youngsters. The emerging technology will reduce the overall turnaround time for dental procedures while improving efficiency of the dental practitioners. For example, introduction of CAD/CAM has reduced designing time for dental crowns and bridges and 3D imaging techniques have improved patient diagnosis and procedure planning. Improvements in the field of dental biomaterials and tissue regenerative material have enabled the dentists to offer more natural and longtime dental solutions. Dentists are now educating their patients about dental products, which has helped in improving customer awareness about products and the latest available technologies. Changing consumer needs and a shift towards cosmetic dentistry will drive the market for hi-end dental solutions.

Stiff competition exists among the industry participants due to product differentiation, technology and pricing. This is more evident among dental companies resulting in companies adopting strategies like technology integration, product improvement and re-branding.

Global Dental Devices and Consumables Market Report

The report segments the Global Dental Devices and Consumables Market based on:

• General and diagnostic devices market by product
• Treatment based devices market by product
• Other dental devices market by product
• Dental consumables market by product

While existing reports have attempted to study end-user attitudes and demographics, they do not provide a complete picture from the industry’s perspective. This report on “Global Dental Devices and Consumables Market” analyzes the market dynamics exclusively from the industry point of view. The report aims at providing a two-dimensional picture of the market by focusing on all aspects of the dental devices market as well as the dental consumables reporting the key trends, which are further analyzed at the micro market levels. The report also includes segments for dental diagnostic devices, dental treatment based devices, consumables and other dental devices market.

Each segment of the report will provide market tables, drivers, restraints and opportunities along with the key players and competitive landscape. This report will also provide more than 100 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report provides over 45 company profiles for each of its sub-segments, such as dental chair manufacturers, implants manufacturers, other devices manufacturers etc.

THE REPORT ANSWERS THE FOLLOWING QUESTIONS

• What are the key market dynamics influencing the market trends?
• Who are the target audience driving the market growth in each of the micro-market?
• Where are key opportunities available to the market players to capitalize on?
• What are the competitive strategies increasingly adopted to combat competition?

What makes our report unique?
• Provision of longest market segmentation in the industry.
• The report provides analysis of patents and more than 45 company profiles giving a competitive outlook.
• The report includes market data for segments such as tools, services and applications for the major geographies – U.S., Europe, Asian and Rest of the World.
• The high level analysis provided by the report analyzes the market prospective for different major market segments along with the identification of opportunities.
• Provides competitive analysis of the major segments and focuses on the global market players and key developments – equipment, devices and technology.

Key questions answered
• Which are the high growth market segments in terms of devices and consumables?
• What are the market forecasts and estimates from the period 2009-14?
• What are the major drivers and opportunities in the market?
• What is the competitive outlook, what are the major tools and services, who are the major players in the market segments?

For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Dental-Equipment-Market-2009-2014–27514.html

Top 10 Medical Device Technology – Aarkstore Enterprise

Technological innovations in the medical device industry have led to a radical transformation in patient care. This report identifies the sectors with the industry’s most important developments related to patient care, clinical outcomes, and new product development. While the scope of the report is limited to the top ten technologies only, it covers almost the entire medical device market.

Scientific and medical technology breakthroughs – such as minimally invasive surgery (MIS) – have accelerated the accuracy of clinical outcomes and have also reduced recovery times and the medical costs borne by patients. This has led to radical transformation in patient care.

IT integration in medical imaging and medical devices has given a significant boost to the healthcare industry, a trend that is apparent in the market growth of drug eluting stents and telemedicine technologies. The markets covered in the report have a current potential of $454.3 billion and are expected to grow at a CAGR of 9.8% between 2009 and 2014.

Market estimates and forecast
The report provides in-depth market estimates and forecast for top ten medical device technologies as follows:
• Diagnostic imaging (nuclear imaging, interventional radiology, capsule endoscopy and others)
• Drug delivery (needle free injections, transdermal systems, inhalation system, infusion system)
• Molecular diagnostics (biosensors, proteomics, nanotechnology, and others)
• Mobility aid technologies
• Minimal/non-invasive surgery (stents, bariatric surgery, medical robotics and others)
• Micro-fluids and MEMS (Miniature medical pressure sensors, bio chips, protein chips)
• Non-invasive monitoring (continuous blood glucose monitoring)
• Biomaterials (bionic limbs, joint replacement, antimicrobial wound dressing and others)
• Bio-implants (neurostimulation and others)
• Tele-medicines

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 100 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 50 company profiles for each of its sub-segments.
What makes our reports unique?
• We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
• Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and minimum 50 micro markets, which are collectively exhaustive and mutually exclusive.
• No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies – US, Europe, APAC, ROW.
• We provide 10% customization – Research shows that more than 40% of the times, clients do not get the specific intelligence they need in multi-client market research reports. We offer 10% customization in our reports at no extra cost. Get the exact market intelligence you require with real value for money.
• 15 pages of high level analysis including benchmarking strategies, best practices and the market’s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
• Comprehensive market analysis for pharmaceutical and biotech companies, medical device manufacturers, pharma-research labs, doctors, physicians and hospitals, medical/pharma associations, retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered
• Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
• What are market estimates and forecasts; which markets are doing well and which are not?
• Where are the gaps and opportunities; what is driving the market?
• Which are the key playing fields? Which are the winning edge imperatives?
• How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and Analysis
The analysts working come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Top-10-Medical-Device-Technology-27527.html

The Future of Biobanks: Regulation, ethics, investment and the humanization of drug discovery – Aarkstore Enterprise

The Future of Biobanks: Regulation, ethics, investment and the humanization of drug discovery

Report Overview

Biobanks collect and store human biospecimens, playing a vital role in the development of novel drugs and diagnostics. In recent years, large population-based biobanks have been established which monitor the health status of participants over time to assess the natural occurrence and progression of common diseases. Hundreds of disease-based biobanks are located around the world, which are a valuable resource for biomarker discovery as well as for studying progression, mortality and responses to treatment.

‘The Future of Biobanks’ is a report published examines major trends in the biobanking industry and identifies the key initiatives to upgrade the biobanking infrastructure. This report explores the applications of biobanks and provides examples of how large sets of high-quality biosamples are creating new ways to diagnose, prevent and treat diseases. The activities of over 180 US biobanks are assessed to illustrate how the scale and scope of biobanking is changing. This report also evaluates the limitations of biobanks, in addition to reviewing the unique legal, regulatory and ethical issues that surround this new frontier of biomolecular research.

Key Findings

• A number of new, high-quality biobanks will accelerate the development of personalized diagnostics and therapeutics over the next decade.
• Increased co-operation between biobanks can advance this progression, although many scientific and political barriers must be overcome.
• An estimated $1bn has been invested in the biobanking industry within the last ten years. The first advances are expected to result in the improved treatment of cancer, and progression for a range of other common diseases will follow.
• Recently established biobanks have reached unprecedented levels of scale, particularly the Taizhou project in China. Studies conducted on the entire population of a country may soon be possible.
• At least 179 biobanks with 345,000 donors exist in the US, most of which were established in the last 10 years.
• As biotechnology companies’ biobanking assets mature in terms of the number of samples collected their R&D productivity and the number of products available for outsourcing will increase

Use this report to…

• Assess the strengths and limitations of biobanks and understand their scientific and commercial relevance with this report’s analysis of biobank-enabled targeted therapeutics and diagnostic/prognostic tests.
• Analyze growth in disease-based biobanks by using this report’s unique review of 180 US-based biobanks by disease type and gain insights into the collaborative networks that can leverage greater sample sizes.
• Evaluate major founder/national population biobanks and gain insights into private sector biobanking with this report’s examination of contract service providers, biomarker discovery companies, pharma collections and research collaborations.
• Review developments in the regulatory framework for biobanking and understand ethical issues including informed consent, withdrawal and ownership, confidentiality and commercialization.

Explore issues including…

• Biobanking expansion. The falling cost of genomic technologies is expanding the scale and scope of biobanking research. This has already resulted in the development of several new diagnostic tests that can improve risk assessment and treatment decisions.
• Potential for personalised medicine. Very few personalized medicines exist, but the creation of large sets of high-quality biosamples should widen the clinical application of new personalized products and services.
• Legal and ethical issues. Although the legal and ethical frameworks that govern biobanking are still evolving, many major issues such as ownership and commercialization are now largely addressed during the consent process.
• Cost of national biobanks. National biobanks have been established in several countries, although their value has been questioned. Conducting large-scale population studies requires significant investment, due to the extremely large collections of biosamples and data involved (including relevant medical history, lifestyle and environmental information).

Discover…

• Why are biobanks a critical resource?
• Which types of biobank are most common?
• What are the most common disadvantages of biobanks?
• Which major drug developers have invested in biobanks?
• What are the major uncertainties surrounding the future of biobanks?
• What growing trend could boost biobanking?
• When will the benefits of biobanking be realized?

For more information, kindly visit :
http://www.aarkstore.com/reports/The-Future-of-Biobanks-Regulation-ethics-investment-and-the-humanization-of-drug-discovery-13972.html

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI – Aarkstore Enterprise

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROIs

Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years. They enable companies to focus on core competencies such as drug discovery or technology development whilst contracting out non-core processes to experts, often at lower costs. As offshore investments begin to mature and provide returns on investment, the opportunity to migrate individual components or whole segments of R&D portfolios will continue to rise.

‘Key Trends in Offshoring Pharmaceutical R&D’ is a report published evaluates the offshore R&D strategies that can reduce development times and improve productivity, with analysis of a variety of strategic partnerships, academic collaborations, and outsourcing opportunities. This report identifies emerging areas of technological and scientific significance across the globe and examines the offshore strategies and investments of the top 20 pharma and biotech companies across Asia, Australia, Central and Eastern Europe, Latin America and the Far East. This report also provides a financial and managerial valuation of leading companies based on their P/E ratio, return on assets (ROA) and return on investment (ROI) and measures company performance against the healthcare industry, pharmaceutical and biotechnology sectors and leading shares of the S&P500.

Key Findings

• Companies that have allocated over 60% of their R&D expenditure offshore have displayed greater shareholder return, operating margins, market capital growth and return on assets.

• The US currently attracts 53% of total industry R&D spend, however it is forecast that 20% of this expenditure will migrate to Asia Pacific by 2010. Australia, China and Singapore are emerging as key areas for scientific and technological investment.

• Leading pharma and biotech companies have undergone major R&D restructuring over the last five years and now adopt a focused, streamlined global approach which is increasingly reliant on offshore strategic partnerships, academic collaboration and outsourcing to establish networks of scientific expertise.

• Scientific and technological excellence within emerging economies is a key incentive for offshore investment, enabling companies to enhance innovation and productivity within their R&D programs.

• Managerial expertise is a critical factor driving the success of offshore investments, helping leading pharma and healthcare companies to outperform their peers and the S&P 500 index in 2008.

Use this report to…

• Assess the offshore R&D strategies of the top 20 pharma and biotech companies with this report’s analysis of offshore investment and deal trends over the last five years.

• Discover which geographic regions have the greatest potential for offshore R&D investment by identifying key areas of technological, scientific and academic expertise across Asia Pacific, Australia, Eastern Europe, Latin America, the Middle East and South Africa.

• Measure how the offshore strategies of the top 20 pharma and biotech companies have influenced their R&D productivity and efficiency with this report’s financial and managerial performance review, comparative analysis of healthcare/pharma/biotech sectors and S&P500 index assessment.

• Identify the key drivers and opportunities for offshore investment with this report’s analysis of major offshoring trends and R&D developments.

Explore issues including…

Shifting focus of R&D strategies. The industry has become more globalized in its R&D approach as part of efforts to improve productivity and efficiency. Networks of offshore partnerships and academic collaborations are now enabling companies to harness external expertise on a project by project basis.

Offshore investment in emerging economies. Companies are increasingly turning to emerging countries to counter the slowing growth of US and European markets. Investing in offshore R&D facilities provides companies with local expertise and a greater understanding of local economies.

Offshore opportunities in tertiary economies. The success of commercial opportunities in emerging markets has expanded the regional scope of investment, with Australia, Israel and Singapore all seen to provide labour arbitrage and access to specialists.

Focused managerial directives are critical. Successful R&D performance is underpinned by a streamlined R&D strategy which is well managed by a team of scientists, technologists and non-scientists which can guide global networks ensuring early go/no go decision making which builds on the core competencies of both internal and external researchers.

Discover…

• Which countries are attracting offshore investment?

• Which areas of research and technology are attracting offshore investment?

• How are the leading pharma and biotech companies changing their R&D programs?

• Which major companies and academic institutions have attracted offshore investment?

• What factors are driving offshore investment?

• What is the financial performance of the leading pharma and biotech companies based on P/E ratio compared to their peers and the S&P500?

• Which companies have delivered the best return on assets and return on investment during the last five years?

• How will offshore investment influence R&D productivity in the future?

 For more information, kindly visit :
http://www.aarkstore.com/reports/Key-Trends-in-Offshoring-Pharmaceutical-R-D-Company-strategies-emerging-markets-and-impact-on-ROI-13950.html